Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women?
Clarkson
Thomas B
TB
Karas
Richard H
RH
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D004195:Disease Models, Animal; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008593:Menopause; D012307:Risk Factors
D015415:Biomarkers; D004967:Estrogens